Adicon Holdings Ltd (HKG: 9860), a China-based independent clinic laboratory (ICL) service provider, has successfully completed its initial public offering (IPO) of 33.2 million shares on the Hong Kong Stock Exchange. The shares were priced at HKD 12.32 (USD 1.58) each, with net proceeds expected to reach HKD 83.9 million (USD 11.7 million).
Established Network and Revenue Growth
Founded in 2004, Adicon operates a robust network of 33 self-operated laboratories that deliver diagnostics and testing services to hospitals and health check centers. In 2022, the company reported impressive revenues of RMB 4.861 billion (USD 682 million). As of December 31, 2022, Adicon has 18 laboratories accredited by ISO 15189, offering a comprehensive testing portfolio that includes over 4,000 medical diagnostic tests, comprising more than 1,700 general tests and over 2,300 specialized tests.
Strategic Use of IPO Proceeds
The net proceeds from the IPO will be strategically allocated to enhance both general and special testing capabilities. Plans include expanding the firm’s network by establishing new laboratories, pursuing co-investment opportunities, and developing new channels. Additionally, Adicon aims to forge strategic partnerships and explore acquisition opportunities within the industry to drive business growth. Investments will also focus on upgrading and expanding existing laboratories, as well as enhancing infrastructure, including logistics facilities, artificial intelligence technology, and information technology systems.-Fineline Info & Tech
